Synsam AB (publ) (SYNSAM.ST)
SEK 42.3
(0.83%)
SEK 42.3
(0.83%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 696 Million SEK | 11.78% |
| 2022 | 552 Million SEK | -12.8% |
| 2021 | 633 Million SEK | 71.08% |
| 2020 | 370 Million SEK | 5.41% |
| 2019 | 351 Million SEK | 34.02% |
| 2018 | 261.9 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 128 Million SEK | -10.49% |
| 2024 Q2 | 255 Million SEK | 250.78% |
| 2023 Q2 | 288 Million SEK | 48.45% |
| 2023 FY | 617 Million SEK | 11.78% |
| 2023 Q4 | 143 Million SEK | -43.25% |
| 2023 Q3 | 252 Million SEK | -12.5% |
| 2023 Q1 | 194 Million SEK | 377.14% |
| 2022 Q1 | 195 Million SEK | 509.38% |
| 2022 Q4 | -70 Million SEK | -137.84% |
| 2022 Q3 | 185 Million SEK | -1.6% |
| 2022 Q2 | 188 Million SEK | -3.59% |
| 2022 FY | 552 Million SEK | -12.8% |
| 2021 Q1 | 171 Million SEK | 61.32% |
| 2021 FY | 633 Million SEK | 71.08% |
| 2021 Q2 | 203 Million SEK | 18.71% |
| 2021 Q4 | 32 Million SEK | -84.16% |
| 2021 Q3 | 202 Million SEK | -0.49% |
| 2020 FY | 370 Million SEK | 5.41% |
| 2020 Q3 | 139 Million SEK | 215.91% |
| 2020 Q1 | 54.5 Million SEK | 0.0% |
| 2020 Q4 | 106 Million SEK | -23.74% |
| 2020 Q2 | 44 Million SEK | -19.27% |
| 2019 FY | 351 Million SEK | 34.02% |
| 2018 FY | 261.9 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AddLife AB (publ) | 585 Million SEK | -18.974% |
| Biotage AB (publ) | 376 Million SEK | -85.106% |
| Bonesupport Holding AB (publ) | 13.93 Million SEK | -4896.411% |
| Doxa AB (publ) | 269.4 Million SEK | -158.352% |
| Elekta AB (publ) | 2.03 Billion SEK | 65.866% |
| iZafe Group AB (publ) | -35.63 Million SEK | 2053.136% |
| Ortivus AB (publ) | -17.61 Million SEK | 4051.851% |
| Ortivus AB (publ) | -17.61 Million SEK | 4051.851% |
| Q-linea AB (publ) | -230.58 Million SEK | 401.838% |
| S2Medical AB (publ) | -15.26 Million SEK | 4659.788% |